After months of rule rewrites, public comments and amendments, Maryland’s state board tasked with controlling the costs of prescription drugs has finalized a framework to evaluate which medications may be eligible for price reductions. The Prescription Drug Affordability Board approved new regulations Monday to establish a process for how the panel will determine which prescription drugs are difficult for Marylanders to afford and would be included in the board’s work to lowering those costs.
